Eli Lilly and Company has reported positive topline results from the pivotal Phase 3 TRIUMPH-2 and TRIUMPH-3 trials of retatrutide, its investigational once-weekly agonist of the GIP, GLP-1 and glucagon receptors. The company said the treatment met the primary weight-loss endpoint in adults whose obesity was complicated by type 2 diabetes or established cardiovascular disease, strengthening the clinical package supporting a planned United States regulatory submission in the first quarter of 2027.
The results expand retatrutide’s Phase 3 evidence beyond adults with obesity who do not have diabetes, a population in which Lilly previously reported average weight reductions exceeding 28% at the highest dose. TRIUMPH-2 and TRIUMPH-3 tested whether the medicine could retain a substantial effect in patients who are generally more difficult to treat because of impaired glucose control, severe obesity, cardiovascular disease or a combination of those conditions.
That distinction matters. Extremely high weight-loss percentages in a broad obesity trial can establish a medicine’s efficacy potential, but regulators, clinicians and payers also need evidence from patients carrying the complications that account for much of obesity’s clinical and economic burden. The latest trials move retatrutide closer to that requirement, although the findings remain company-reported topline data rather than a fully published assessment of efficacy and safety.
Why do the TRIUMPH-2 results matter for obesity complicated by type 2 diabetes?
TRIUMPH-2 was an 80-week, randomised, double-blind and placebo-controlled Phase 3 trial involving approximately 1,150 adults with type 2 diabetes and either obesity or overweight. Participants were assigned to weekly retatrutide doses of 4 mg, 9 mg or 12 mg, or to placebo, with those receiving retatrutide beginning at 2 mg and escalating every four weeks until reaching their target dose.
Lilly reported average weight reductions of 12.7% with 4 mg, 19.1% with 9 mg and 20.8% with 12 mg, compared with 4% for placebo. The mean starting weight was 106.4 kg and the average baseline body mass index was 38.2 kg per square metre. In absolute terms, participants receiving the highest dose lost an average of 22.5 kg, or 49.6 pounds, by week 80.
The study also produced reductions in glycated haemoglobin, or A1C, of 1.4 percentage points with 4 mg, 1.6 points with 9 mg and 1.5 points with 12 mg. The placebo group recorded a reduction of 0.2 points from the mean baseline A1C of 7.7%.
The results are clinically relevant because patients with type 2 diabetes have frequently achieved less weight loss than participants without diabetes in trials of incretin-based obesity therapies. The TRIUMPH-2 data suggest that retatrutide’s three-receptor mechanism can generate substantial weight reduction while simultaneously improving glycaemic control in this more treatment-resistant population.
The dose response, however, deserves closer examination. Moving from 4 mg to 9 mg produced a considerable increase in average weight loss, while the incremental improvement between 9 mg and 12 mg was smaller. A1C reduction was also numerically greatest with 9 mg rather than the maximum dose. Those findings do not establish that 9 mg offers the best overall balance, particularly before the full statistical analyses and safety tables are available, but they may become important when regulators and clinicians assess dose selection.
A commercially successful obesity drug does not necessarily require every patient to reach the highest available dose. Lilly could gain flexibility if lower or intermediate retatrutide doses provide sufficient efficacy for some patients while reducing treatment discontinuation, tolerability problems or manufacturing demand.
What does TRIUMPH-3 establish, and what can it not say about cardiovascular outcomes?
TRIUMPH-3 enrolled approximately 1,950 adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. Participants had a body mass index of at least 35 kg per square metre and were randomised to receive retatrutide 9 mg, retatrutide 12 mg or placebo.
After 80 weeks, average weight fell by 21.6% with 9 mg and 22.6% with 12 mg, compared with 3.2% for placebo. Participants receiving the highest dose lost an average of 25.3 kg, or 55.8 pounds, from a mean starting weight of 111.4 kg.
Lilly also reported improvements in several cardiovascular risk markers at the 12 mg dose, including a 37% reduction in triglycerides, a 16.5% reduction in non-HDL cholesterol, a 9.3 mmHg reduction in systolic blood pressure, a 19-centimetre reduction in waist circumference and a 51.2% reduction in high-sensitivity C-reactive protein.
Those measures strengthen the cardiometabolic rationale for retatrutide, but they are not substitutes for evidence that the drug reduces heart attacks, strokes, cardiovascular deaths or other major clinical outcomes. Improvements in weight, blood pressure, lipids and inflammatory markers can be encouraging, yet cardiovascular benefit must be established through an adequately powered outcomes trial.
That distinction is particularly important because the event analyses disclosed from TRIUMPH-3 were inconclusive. Lilly reported 44 broadly defined MACE-5 events among participants assigned to pooled retatrutide doses and 52 among those receiving placebo, producing a hazard ratio of 0.82 with a 95% confidence interval ranging from 0.55 to 1.22.
For the narrower MACE-3 measure covering cardiovascular death, heart attack or stroke, 27 events occurred in the retatrutide groups and 23 in the placebo group. The resulting hazard ratio was 1.12, with a wide confidence interval of 0.64 to 1.96. Both intervals crossed 1, meaning the study did not establish either a cardiovascular benefit or an increased cardiovascular risk.
The event count was lower than Lilly had anticipated, limiting the trial’s ability to produce a definitive cardiovascular conclusion. The appropriate interpretation is therefore not that retatrutide reduced cardiovascular events, nor that it caused an increase in MACE-3. TRIUMPH-3 primarily provides weight-loss and safety evidence in a high-risk cardiovascular population.
A more conclusive answer is expected from TRIUMPH-Outcomes, an event-driven Phase 3 trial involving about 10,000 adults with obesity and atherosclerotic cardiovascular disease or chronic kidney disease. The study is designed to assess cardiovascular and kidney outcomes and is currently expected to continue until 2029.
Is retatrutide’s safety profile manageable enough for broad long-term obesity use?
Gastrointestinal adverse events remained the most frequently reported tolerability problem across both trials, consistent with the wider incretin drug class. Diarrhoea, nausea, constipation, reduced appetite and vomiting occurred more frequently with retatrutide than with placebo, although Lilly described most events as mild or moderate and said the majority resolved during treatment.
In TRIUMPH-2, diarrhoea was reported in 27.4% of participants receiving 4 mg, 33.5% receiving 9 mg and 33.6% receiving 12 mg, compared with 13.2% for placebo. Nausea increased from 13.7% at 4 mg to 28% at 12 mg, while vomiting rose from 5.5% to 15.7%.
Adverse-event discontinuation rates were 3.8% with 4 mg, 11.6% with 9 mg and 7.7% with 12 mg, compared with 4.9% for placebo. The apparently higher discontinuation rate at 9 mg than at 12 mg requires further context and should not be interpreted as evidence that the maximum dose was more tolerable.
In TRIUMPH-3, discontinuations due to adverse events affected 9.8% of participants receiving 9 mg and 13.5% receiving 12 mg, compared with 4.8% in the placebo group. That dose-associated increase may be commercially meaningful because obesity treatment is intended to be long term and real-world persistence is influenced by tolerability as much as headline efficacy.
Lilly also disclosed higher rates of dysesthesia, an abnormal skin sensation that can include tingling or altered sensitivity. In TRIUMPH-2, dysesthesia occurred in 4.5%, 5.6% and 7.3% of the respective retatrutide dose groups, compared with 0.7% for placebo. In TRIUMPH-3, the rate was 6.4% with either dose and 1.3% with placebo.
Dysesthesia has been watched closely since earlier retatrutide studies, although the available information does not indicate that most cases were severe or persistent. Detailed presentations will need to show event duration, treatment interruption, dose reduction, recurrence and whether symptoms materially affected quality of life.
The topline announcement did not provide a comprehensive breakdown of serious adverse events, pancreatitis, gallbladder events, hypoglycaemia, heart-rate changes or deaths by treatment group. Their absence from the announcement should not be interpreted as evidence that such events did not occur. Regulators will evaluate the complete safety database, including events from across the retatrutide development programme.
How does this data package strengthen the planned 2027 FDA submission?
Lilly said the latest results complete the clinical data package needed to support global regulatory submissions for retatrutide in obesity, knee osteoarthritis pain and obstructive sleep apnoea. The company plans to submit a Biologics License Application to the United States Food and Drug Administration during the first quarter of 2027, after completing the required chemistry, manufacturing and controls package.
The timing means the immediate development risk is shifting. Retatrutide has now generated positive company-reported results from five Phase 3 studies, including TRIUMPH-1 in obesity without diabetes, TRIUMPH-4 in obesity with knee osteoarthritis, TRANSCEND-T2D-1 in type 2 diabetes, and the newly reported TRIUMPH-2 and TRIUMPH-3 studies.
Clinical efficacy is no longer the only major question. Lilly must assemble consistent datasets across multiple populations and doses, demonstrate that its proposed dosing schedule is justified, complete product characterisation and manufacturing validation, and provide regulators with an integrated analysis of gastrointestinal events, dysesthesia and other potential class or molecule-specific risks.
A planned application is not equivalent to submission, acceptance for review or approval. The first-quarter 2027 target also depends on Lilly finishing its chemistry, manufacturing and controls work as expected. Any delay involving manufacturing validation, analytical comparability or documentation could affect the filing timetable even if the clinical results remain supportive.
Detailed publication will be another important milestone. The TRIUMPH-2 and TRIUMPH-3 findings are currently available as topline company disclosures, while peer-reviewed papers and complete medical-meeting presentations remain pending. Those fuller datasets should reveal treatment-regimen estimands, missing-data handling, statistical testing hierarchies, serious adverse events and the proportion of patients achieving different weight-loss thresholds.
Where could retatrutide fit alongside Zepbound, Foundayo and rival obesity drugs?
Retatrutide could give Eli Lilly a tiered cardiometabolic portfolio rather than merely serving as a replacement for Zepbound. Tirzepatide already provides an established injectable option, while the oral GLP-1 medicine orforglipron, marketed as Foundayo, addresses patients who may prefer an oral treatment.
Retatrutide may be positioned for patients with greater weight-loss requirements, severe obesity or complications such as obstructive sleep apnoea, knee osteoarthritis, diabetes and cardiovascular disease. Such a strategy could allow Lilly to match treatment intensity with clinical need, tolerability and payer willingness to cover therapy.
The Phase 3 weight-loss results appear highly competitive within the obesity-treatment field, but direct superiority over tirzepatide, semaglutide or future combination therapies has not been demonstrated. Differences in patient populations, baseline weight, diabetes status, treatment duration, dose escalation, adherence and statistical methods prevent reliable conclusions based on separate trials.
Commercial success will also depend on issues that clinical percentages cannot answer. These include price, insurance coverage, manufacturing capacity, dose availability, patient persistence and whether payers reserve the drug for individuals who have not achieved sufficient results with less expensive therapies.
The glucagon component of retatrutide’s mechanism is intended to complement the appetite and metabolic effects associated with GIP and GLP-1 receptor activation. Earlier peer-reviewed Phase 2 research reported average weight loss of up to 24.2% at 48 weeks, supporting advancement into Phase 3, but also identified dose-related gastrointestinal events and temporary dose-dependent increases in heart rate.
The new results indicate that the efficacy signal persisted in substantially larger trials and across more complicated patient groups. They do not eliminate the need to understand long-term cardiovascular outcomes, treatment persistence or whether very large weight reductions can be maintained after dose changes or discontinuation.
Why did Eli Lilly shares rise without a more dramatic market repricing?
Eli Lilly shares rose 1.97% to $1,185.87 on July 23, the day the TRIUMPH-2 and TRIUMPH-3 results were announced, and gained a further 0.86% during the following session. The July 23 closing price was about 5% below the stock’s then 52-week high of $1,249.45.
The positive but measured reaction suggests investors had already assigned substantial value to retatrutide after earlier Phase 3 results. The stock had also been supported by rapid growth across Lilly’s existing obesity and diabetes franchise, leaving a high threshold for any single clinical update to produce a major revaluation.
From an investor perspective, the latest results are best viewed as regulatory de-risking rather than an unexpected discovery. Retatrutide performed strongly in two important populations and kept the planned 2027 filing on track, but the market still lacks a regulatory decision, an approved label, pricing information and evidence from the dedicated cardiovascular and kidney outcomes programme.
The remaining commercial question is not simply whether retatrutide can produce greater weight loss. It is whether Eli Lilly can translate that efficacy into an approvable safety profile, scalable supply, durable patient use and payer access without weakening the economics of its existing cardiometabolic products.
Retatrutide has now crossed another important clinical threshold. The next test will take place less visibly, inside the integrated safety analyses, manufacturing package and regulatory review that determine whether impressive Phase 3 percentages can become a widely available treatment.
